雖然這篇Brodalumab鄉民發文沒有被收入到精華區:在Brodalumab這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]Brodalumab是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1新藥介紹:Brodalumab (Lumicef® ) - 國泰綜合醫院
建議劑量為第0、1、2 週和之後每2 週. 皮下注射brodalumab 210 mg。若治療12 至. 16 週後,未能達到適當的治療反應時,因繼. 續使用超過16 週亦不 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2【免疫醫學】2015年新藥發展戲劇王:Brodalumab
Brodalumab 是一株人類免疫球蛋白單株抗體,可以作為免疫抑制劑,新藥發展的目標是治療乾癬(Psoriasis;又稱作牛皮癬)與乾癬性關節炎(Psoriasis ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3Brodalumab - Wikipedia
Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Brodalumab in psoriatic arthritis: results from the ... - PubMed
由 PJ Mease 著作 · 2021 · 被引用 28 次 — Brodalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo. Brodalumab was well tolerated ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Efficacy and Safety of Brodalumab Compared With ...
2020年9月1日 — The trial investigates the efficacy and safety of brodalumab against guselkumab in treatment for patients with moderate-to-severe plaque ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6BRODALUMAB | Drug | BNF content published by NICE
Brodalumab is a recombinant human monoclonal antibody that binds with high affinity to interleukin-17RA and blocks the activity of pro-inflammatory ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Brodalumab in psoriatic arthritis: results from the randomised ...
Brodalumab has demonstrated efficacy in a phase II trial of patients with psoriatic arthritis (PsA). What does this study add? These phase III trials summarise ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8SILIQ (brodalumab)| Treatment for Moderate to Severe Plaque ...
SILIQ ® injection is a prescription medicine used to treat adults with moderate to severe plaque psoriasis: ... It is not known if SILIQ is safe and effective in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Siliq (brodalumab) dosing, indications, interactions, adverse ...
brodalumab decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10立美西膚皮下注射劑210 毫克 - Kyowa Kirin
Brodalumab (Genetical Recombination). 含量. 每1 注射針筒. (1.5 毫升)中. 210 毫克. 關於病人用藥說明書. 病人用藥說明書的製作用意在於讓病人與家屬可正確了解 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11Phase 3 Studies Comparing Brodalumab with Ustekinumab in ...
由 M Lebwohl 著作 · 2015 · 被引用 674 次 — BackgroundEarly clinical studies suggested that the anti–interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12Brodalumab | DermNet NZ
Brodalumab is used for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13Efficacy of Brodalumab and Guselkumab in Psoriasis | PTT
Purpose: Both brodalumab and guselkumab improve skin clearance in patients with moderate-to-severe plaque psoriasis after inadequate response to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Brodalumab: A new way to inhibit IL‐17 in psoriasis - Wiley ...
Brodalumab is a fully human anti-IL-17 receptor A (IL-17RA) IgG2 monoclonal antibody that inhibits the biological activity of interleukin 17A, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15Brodalumab - an overview | ScienceDirect Topics
Brodalumab is a human monoclonal antibody IgG2κ directed against the interleukin 17A receptor. Brodalumab is indicated for the treatment of moderate to severe ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16Brodalumab Syringe - Uses, Side Effects, and More - WebMD
Find patient medical information for brodalumab subcutaneous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Brodalumab (Subcutaneous Route) Side Effects - Mayo Clinic
Brodalumab injection is used to treat moderate to severe plaque psoriasis in patients who may benefit from receiving phototherapy ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18Kyntheum 210 mg Solution for Injection - (emc)
Brodalumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. For the full list of excipients, see section 6.1. 3.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Brodalumab: Generic, Uses, Side Effects, Dosages ... - RxList
Brodalumab (Siliq) is used for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Brodalumab Is Associated with High Rates of Complete ...
Brodalumab is a fully human monoclonal antibody with a unique mechanism of action. ... Brodalumab is currently approved for the treatment of moderate-to-severe ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Brodalumab Uses, Side Effects & Warnings - Drugs.com
Brodalumab is used to treat moderate to severe plaque psoriasis in adults. Brodalumab is usually given after other treatments have failed.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Kyntheum, INN-brodalumab - European Medicines Agency |
2017年5月18日 — International non-proprietary name: brodalumab. Procedure No. EMEA/H/C/003959/0000. Note. Assessment report as adopted by the CHMP with all ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23BRODALUMAB - British Association of Dermatologists
What is brodalumab and how does it work? Brodalumab is a biologic medicine that has been designed to treat psoriasis. It works by.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24Brodalumab - AstraZeneca/Bausch Health Companies/Kyowa ...
Brodalumab is a fully human immunoglobulin G2 monoclonal antibody, being developed by Kyowa Kirin (formerly Kyowa Hakko Kirin) and Bausch Health Companies.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25CE2 EFFICACY OF BRODALUMAB AND GUSELKUMAB IN ...
Brodalumab and guselkumab are approved for the treatment of moderate to severe plaque psoriasis in adult patients eligible for systemic therapies. In the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26Brodalumab: Indication, Dosage, Side Effect, Precaution - MIMS
Brodalumab : Belongs to the class of interleukin inhibitors. Used as immunosuppressants.,
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Human IL-17RA/IL-17R (Research Grade Brodalumab ...
View Human IL-17RA/IL-17R (Research Grade Brodalumab Biosimilar) Antibody (MAB10547-100) datasheet.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Brodalumab in the treatment of moderate to severe psoriasis ...
Data from the brodalumab pivotal trials showed that previous exposure to biologic drugs did not affect brodalumab's efficacy.2. However, how patients respond to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Brodalumab in the treatment of chronic plaque psoriasis
Brodalumab has a rapid onset of action, improves psoriasis-associated inflammation and clinical symptoms, and is efficacious in difficult-to-treat areas such as ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30brodalumab | Ligand page - IUPHAR/BPS Guide to ...
Comment: Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It targets the interleukin 17 receptor A (IL17RA).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31Brodalumab Antibody (MA5-41942) - Thermo Fisher
Invitrogen Anti-Brodalumab Recombinant Monoclonal, Catalog # MA5-41942. Tested in Western Blot (WB) and ELISA (ELISA) applications.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32Brodalumab Linked With Improved Symptoms, Satisfaction ...
Japanese patients with psoriasis reported improved objective symptoms and satisfaction with brodalumab.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Troubled psoriasis med brodalumab debuts in Japan with ...
Kyowa Hakko Kirin is rolling out the psoriasis med brodalumab this week in Japan, its first world market, but it faces.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Siliq (brodalumab) approved by the US FDA for adult patients ...
AstraZeneca's partner Valeant Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Siliq (brodalumab) Label - Accessdata.fda.gov
SILIQ™ (brodalumab) injection, for subcutaneous use. Initial U.S. Approval: 2017. WARNING: SUICIDAL IDEATION AND BEHAVIOR. See full prescribing information ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36Dose optimization of brodalumab in moderate-to-severe ...
Brodalumab, a monoclonal antibody that targets the interleukin-17 receptor, is a new treatment option for moderate-to-severe plaque ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Effect of IL-17 receptor A blockade with brodalumab in ...
brodalumab, psoriasis, psoriatic arthritis, asthma, ... for these agents with a focus on IL-17 receptor blockade mediated by brodalumab, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Brodalumab shows low rate of malignancy in psoriasis treatment
Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody used to treat adults with moderate to severe plaque psoriasis, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39Brodalumab effective for psoriasis patients with skin of color
Brodalumab is a fully human monoclonal antibody that binds to the interleukin 17 receptor A. The AMAGINE I, II and III are randomized, double ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40A Case of Rebound Due to Brodalumab Discontinuation
Brodalumab, despite other drugs such as Ixekizumab and Secukinumab, targets the IL-17 receptor and not on the circulating cytokine, performing a faster ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41Brodalumab in treatment of moderate to severe plaque psoriasis
FDA have, however, approved brodalumab for psoriasis with notice about risk of suicide. During clinical trials, six patients treated with the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42Brodalumab Boosts Response in Psoriatic Arthritis - Medpage ...
Brodalumab, a monoclonal antibody targeting the interleukin-17 receptor A (IL17RA), showed efficacy for the musculoskeletal components of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43Brodalumab Approved for Psoriasis - Rheumatology Network
Brodalumab, which is administered as an injection, is a monoclonal antibody that neutralizes IL-17 receptor type A - an important cytokine in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44Subject: Brodalumab (Siliq®) Injection - Medical Coverage ...
Brodalumab was approved by the US Food and Drug. Administration (FDA) in February 2017 for “the treatment of moderate to severe plaque ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45FDA approves brodalumab - The Antibody Society
Brodalumab, an IgG2 monoclonal antibody targeting the interleukin (IL)-17 receptor, inhibits the biological activity of IL-17A, IL-17F and other ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Brodalumab for the Treatment of Psoriasis: A Review of Phase ...
Conclusion: Use of brodalumab revealed prompt clinical improvement and a favorable short-term safety profile in phase III trials, although ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47Siliq (Brodalumab) a New IL-17RA Antagonist Approved for ...
Brodalumab is a human monoclonal immunoglobulin G2 antibody that is selectively binding to human IL-17RA, thereby inhibiting brodalumab's interaction with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48What is Brodalumab? - GoodRx
an unusual or allergic reaction to brodalumab, other medicines, foods, dyes or preservatives; pregnant or trying to get pregnant; breast-feeding. Buy Brodalumab ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49New data show that LEO Pharma's Kyntheum® (brodalumab ...
New data show that LEO Pharma's Kyntheum ® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50brodalumab - 成分、適應症、副作用 - KingNet國家網路醫藥
brodalumab 的用法與用量、成分、適應症、副作用,brodalumab仿單與說明資料|藥典|KingNet國家網路醫藥|Second Opinion.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51Long-term findings from two phase 3 psoriasis studies
Brodalumab in patients with or without previous use of biologic agents: Long-term findings from two phase 3 psoriasis studies. Green L, Menter A, Boh E, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52Use of brodalumab for the treatment of psoriasis and psoriatic ...
Psoriasis is a chronic immune-mediated disease that affects 2–3% of the population worldwide. Over the past two decades new data on the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53brodalumab | CS Mott Children's Hospital | Michigan Medicine
Brodalumab affects your immune system. You may get infections more easily. Call your doctor if you have symptoms such as fever, chills, cough, skin sores, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54Amgen to Terminate Participation in Co-development and ...
Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Brodalumab shows promise for psoriatic arthritis - Medicine ...
AMVISION-1 and AMVISION-2 trials: Brodalumab may be a promising treatment option for psoriatic arthritis.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56Medline ® Abstract for Reference 185 of 'Treatment of ...
185: PubMed |; TI: Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. AU: Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Brodalumab Injection: MedlinePlus Drug Information
It is not known whether brodalumab injection causes suicidal thoughts and behavior. Tell your doctor and pharmacist if you have a history of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58Amgen's termination of brodalumab stuns psoriasis world
Brodalumab was also in codevelopment by Amgen and AstraZeneca for psoriatic arthritis and axial spondyloarthritis.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59Brodalumab | Memorial Sloan Kettering Cancer Center
Brodalumab. Adult Medication. Share. Print. This information from Lexicomp ® explains what you need to know about this medication, including what it's used ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60Siliq (Brodalumab) a New IL-17RA Antagonist Approved for ...
Brodalumab Receives FDA Approval for Plaque Psoriasis · Mechanism of Action · Dosing and Administration · Phase 3 Clinical Trials · Adverse Reactions.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61Brodalumab for the Treatment of Psoriasis: A ... - eScholarship
Preclinical and phase II studies of brodalumab, a high-affinity IL-17 receptor monoclonal antibody, have been encouraging.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62A New Way to Inhibit IL-17 in Psoriasis: Real-Life Use of ...
Case Series | OPEN ACCESS DOI: 10.23937/2469-5750/1510075. A New Way to Inhibit IL-17 in Psoriasis: Real-Life Use of Brodalumab Goes Beyond Clinical Trials ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63Brodalumab | 皮膚專科醫師蔡昌霖-乾癬+孕婦小兒皮膚病+孕婦 ...
美國FDA在2017年2月底時核准了第三種抗IL-17的生物製劑:Brodalumab (商品名Siliq). 至此三種IL-17阻斷劑的生物製劑都已經順利在美日上市了.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64Brodalumab injection - Cleveland Clinic
Get information on Brodalumab injection including uses, dosage details, medication side-effects and drug interaction facts from Cleveland Clinic's health ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65Leo Pharma to market AstraZeneca's brodalumab outside ...
Leo Pharma has acquired the rights to develop and market psoriasis treatment brodalumab outside Europe. The Danish dermatology specialist ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66Brodalumab: Uses, Interactions, Mechanism of Action
Brodalumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67brodalumab (Kyntheum) - Scottish Medicines Consortium
following a resubmission: brodalumab (Kyntheum®) is accepted for restricted use within NHSScotland. Indication under review: for the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Spotlight on brodalumab in the treatment of plaque psoriasis
In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69KYNTHEUM (brodalumab), interleukin inhibitor ...
KYNTHEUM (brodalumab), interleukin inhibitor immunosuppressant. DERMATOLOGY - New medicinal product. Opinions on drugs - Posted on Jul 19 2018 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70Amgen Halts Co-Development of Brodalumab with AstraZeneca
Amgen has ended its co-development of the drug candidate brodalumab with AstraZeneca, citing what it called “events of suicidal ideation and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71American Journal of Respiratory and Critical Care Medicine
Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72brodalumab | CADTH
brodalumab. Project Status: Complete. Therapeutic Area: Psoriasis, moderate to severe plaque. Manufacturer: Valeant Canada LP.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73Brodalumab, 编辑, 古斯库单抗的临床试验
该试验调查了brodalumab 对guselkumab 治疗的状态和安全性对于有一些症状的患者的中度至重度斑块状银屑病患者优特克治疗后。。临床试验注册。 ICH GCP。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74Valeant Announces List Price of Brodalumab - BioPharm ...
Valeant's Siliq (brodalumab) injection will be listed for $3500 a month in the United States, the company said on April 21, 2017.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
The FDA has approved brodalumab (Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76Benefit assessment according to §35a Social Code Book V
Brodalumab (plaque psoriasis) – Benefit assessment according to §35a Social ... Extract of dossier assessment: Brodalumab (plaque psoriasis) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Brodalumab vs. Ustekinumab for Psoriasis - NEJM Journal ...
Both agents are very active against psoriatic skin disease, but brodalumab works more rapidly and is more effective.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Brodalumab - A New Promising Treatment for Psoriasis
Brodalumab is a monoclonal antibody that inhibits the interleukin-17 pathway. It blocks the action of 17A, 17F, 17A/F heterodimer, and 17E. A ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79Brodalumab Overview - Creative Biolabs
Brodalumab is a fully human anti-interleukin 17 receptor A (IL-17RA) IgG2 monoclonal antibody developed by Amgen, Inc. as AMG 827. It been investigated in a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80brodalumab - DrugCentral
Synonyms: kyntheum; brodalumab; AMG 827; AMG-827. Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Fallbericht einer unter Brodalumab (Kyntheum ...
Brodalumab (Kyntheum®) ist ein rekombinanter, vollständig humaner, monoklonaler IgG2-Antikörper, der mit hoher Affinität an die IL17-Rezeptor A- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82斑块性银屑病新药brodalumab临床III期结果优异 - 梅斯医学
治疗斑块性银屑病药物brodalumab在临床三期对比研究中击败了畅销药物Stelara。这一研究结果也将有利于brodalumab在欧盟和美国市场的药物审批过程。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Brodalumab
An interleukin-17 (IL-17) receptor inhibitor used to treat psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Brodalumab|Kyntheum|51|2017 | PZ – Pharmazeutische Zeitung
Brodalumab ist ein monoklonaler Antikörper, der selektiv an die Interleukin(IL)-17-Rezeptor-Untereinheit A bindet.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Advances in Psoriasis: A Multisystemic Guide
Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today. 2017;53(5):283–97. 18. Papp K, Leonardi C, Menter A, et al.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86银屑病药物Brodalumab在3期试验中优于优特克单抗
Brodalumab 治疗患者中,210mg剂量组、基于体重治疗组、140mg剂量组分别有44.4%、33.6%和25.7%的患者达到皮肤疾病总清除率(PASI 100),相比之下,优特克单 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87乾癬與皮膚疾病的免疫生物製劑治療 - 臺灣醫學會
第四代的產品,國內則以Cosentyx為代表,抑制IL-17,類似作用的ixekizumab, brodalumab也在國外上市。,此類產品藉由中和IL-17,直接作用在表皮細胞發炎源頭,在密集 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Good news for psoriasis sufferers in Scotland - Hub Publishing
Scottish Medicines Consortium accepts use of Kyntheum ® ▽ (brodalumab) for eligible patients with moderate-to-severe plaque psoriasis.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Siliq (brodalumab) - MPR
Generic name: Brodalumab. ▫ Pharmacological class: Interleukin-17A antagonist. ▫ Strength and Formulation: 210mg/1.5mL; soln for SC inj; preservative-free.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90Mild to Moderate and Moderate to Severe Psoriasis (Set)
Brodalumab Brodalumab (AMG827) is a human IgG2κ monoclonal antibody that binds with high affinity to IL-17RA. In other words, this antibody antagonizes the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91Siliq injection 210mg/1.5ml(brodalumab 布罗达单抗预充注射器)
新型IL17A受体抗体Siliq(brodalumab)获FDA批准,用于治疗顽固性银屑病。 近日,美国食品和药物管理局批准了Siliq(brodalumab)用于治疗成人中度至 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92Kyntheum - LEO Pharma
Principio activo: brodalumab. ▽ Este medicamento está sujeto a seguimiento adicional, lo que agilizará la detección de nueva información sobre su seguridad ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93Kyntheum (brodalumab) - Tu Farmacéutico de Guardia
Debe inyectar el contenido de la jeringa de brodalumab de forma subcutánea. La dosis habitual recomendada de inicio es de 210 mg por inyección subcutánea en las ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#94Kyntheum® brodalumab | De un vistazo | LEO Pharma
Kyntheum ® es un anticuerpo monoclonal humano y el único tratamiento biológico para la psoriasis en placas de moderada a grave, cuya diana selectiva es la ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
brodalumab 在 コバにゃんチャンネル Youtube 的最讚貼文
brodalumab 在 大象中醫 Youtube 的最佳貼文
brodalumab 在 大象中醫 Youtube 的最讚貼文